Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by
the presence of circulating plasma cells. It is classified as either primary PCL occurring at …

c-MYC is one of the most essential transcriptional factors, regulating a diverse array of
cellular functions, including proliferation, growth, and apoptosis. Dysregulation of c-MYC is …

MYC locus rearrangements—often complex combinations of translocations, insertions,
deletions and inversions—in multiple myeloma (MM) were thought to be a late progression …

Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …

Hematopoiesis is a process capable of generating millions of cells every second, as
distributed in many cell types. The process is regulated by a number of transcription factors …

Abstract Purpose of Review We discuss current topics on the definition of plasma cell
leukemia and the distinction between plasma cell leukemia and multiple myeloma …

Secondary MYC translocations in myeloma have been shown to be important in the
pathogenesis and progression of disease. Here, we have used a DNA capture and …

Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell proliferative
disorder with a very poor prognosis and with distinct biologic, clinical, and laboratory …

Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with a guarded
prognosis. The diagnosis is confirmed when peripheral blood plasma cells (PCs) exceed …

Purpose Primary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a
poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all …